Trial
NCT01614405
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Alberta
Collaborators
Abbott; Gilead Sciences; Canadian Institutes of Health Research (CIHR)
Condition
Primary Biliary Cirrhosis
Intervention
TDF/FTC/LPV/r
Why stopped
Protracted gastrointestinal symptoms were experienced by most patients who were subsequently found to be in the treatment arm on LPV/r. This observation resulted in cessation of enrolment and a decision not to continue the RCT
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-21